We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Cymabay Therapeutics Inc (CBAY) USD0.0001

Sell:$32.47 Buy:$32.48 Change: $0.005 (0.02%)
NASDAQ:0.82%
Market closed |  Prices as at close on 18 March 2024 | Switch to live prices |
Takeover

Cymabay Therapeutics Inc USD0.0001

Type:
Takeover
Shareholder action required:
Yes
Status:
Update Pending
Details (last updated 7 Mar 2024)

Pacific Merger Sub, a wholly owned subsidiary of Gilead Sciences Inc, has made an offer to buy Cymabay Therapeutics Inc shares for USD32.50 per share.

 

If you don’t want to accept the offer, you don’t need to do anything. Depending on the level of acceptance the offeror may choose to delist or compulsorily acquire the remaining shares at a later date.

 

Accept the offer – Act by noon on Monday 18 March 2024

 

The proceeds will be converted to Pound Sterling upon receipt, based on the prevailing exchange rate at the time and our standard currency conversion fees.

 

Full details of this event will be sent to Qualifying Hargreaves Lansdown clients by either post or secure message. Please note that any instruction you give must be based on the full details provided in the letter/message and not on the summary information outlined above.

×
Sell:$32.47
Buy:$32.48
Change: $0.005 (0.02%)
Market closed |  Prices as at close on 18 March 2024 | Switch to live prices |
Takeover

Cymabay Therapeutics Inc USD0.0001

Type:
Takeover
Shareholder action required:
Yes
Status:
Update Pending
Details (last updated 7 Mar 2024)

Pacific Merger Sub, a wholly owned subsidiary of Gilead Sciences Inc, has made an offer to buy Cymabay Therapeutics Inc shares for USD32.50 per share.

 

If you don’t want to accept the offer, you don’t need to do anything. Depending on the level of acceptance the offeror may choose to delist or compulsorily acquire the remaining shares at a later date.

 

Accept the offer – Act by noon on Monday 18 March 2024

 

The proceeds will be converted to Pound Sterling upon receipt, based on the prevailing exchange rate at the time and our standard currency conversion fees.

 

Full details of this event will be sent to Qualifying Hargreaves Lansdown clients by either post or secure message. Please note that any instruction you give must be based on the full details provided in the letter/message and not on the summary information outlined above.

×
Sell:$32.47
Buy:$32.48
Change: $0.005 (0.02%)
Market closed |  Prices as at close on 18 March 2024 | Switch to live prices |
Takeover

Cymabay Therapeutics Inc USD0.0001

Type:
Takeover
Shareholder action required:
Yes
Status:
Update Pending
Details (last updated 7 Mar 2024)

Pacific Merger Sub, a wholly owned subsidiary of Gilead Sciences Inc, has made an offer to buy Cymabay Therapeutics Inc shares for USD32.50 per share.

 

If you don’t want to accept the offer, you don’t need to do anything. Depending on the level of acceptance the offeror may choose to delist or compulsorily acquire the remaining shares at a later date.

 

Accept the offer – Act by noon on Monday 18 March 2024

 

The proceeds will be converted to Pound Sterling upon receipt, based on the prevailing exchange rate at the time and our standard currency conversion fees.

 

Full details of this event will be sent to Qualifying Hargreaves Lansdown clients by either post or secure message. Please note that any instruction you give must be based on the full details provided in the letter/message and not on the summary information outlined above.

×
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Listed below are trades carried out by directors and other individuals which are required to be notified to the market.


Recent deals

Date Name Position (if held) Deal type Number of
shares dealt
Price Value of trade Shares
remaining
N/A There were no director deals placed within the selected time period of 3 months
13 Sep 2023 AVORO CAPITAL ADVISORS LLC N/A Regular sell transaction (market) 1,200.00 $1.07 $1,287.69 250.00
12 Sep 2023 AVORO CAPITAL ADVISORS LLC N/A Regular sell transaction (market) 1,800.00 $1.00 $1,799.40 300.00
12 Sep 2023 AVORO CAPITAL ADVISORS LLC N/A Regular purchase transaction 583,771.00 $17.13 $9,999,938.85 583,771.00
13 Sep 2023 AVORO CAPITAL ADVISORS LLC N/A Regular sell transaction (market) 1,200.00 $1.07 $1,287.69 250.00
12 Sep 2023 AVORO CAPITAL ADVISORS LLC N/A Regular sell transaction (market) 1,800.00 $1.00 $1,799.40 300.00
12 Sep 2023 AVORO CAPITAL ADVISORS LLC N/A Regular purchase transaction 583,771.00 $17.13 $9,999,938.85 583,771.00
17 Apr 2023 Kim, Dennis D N/A Sell (option related) 112,219.00 $9.54 $1,070,535.59 20,000.00
13 Apr 2023 Kim, Dennis D N/A Sell (option related) 7,781.00 $8.98 $69,880.38 20,000.00
28 Mar 2023 Kim, Dennis D N/A Sell (option related) 100.00 $8.99 $898.50 20,000.00

5 most significant trades

Date Name Position (if held) Deal type Number of
shares dealt
Price Value of trade Shares
remaining
N/A There were no director deals placed within the selected time period of 3 months
12 Sep 2023 AVORO CAPITAL ADVISORS LLC N/A Regular purchase transaction 583,771 $17.13 $9,999,938.85 583,771.00
12 Sep 2023 AVORO CAPITAL ADVISORS LLC N/A Regular sell transaction (market) 1,800 $1.00 $1,799.40 300.00
13 Sep 2023 AVORO CAPITAL ADVISORS LLC N/A Regular sell transaction (market) 1,200 $1.07 $1,287.69 250.00
12 Sep 2023 AVORO CAPITAL ADVISORS LLC N/A Regular purchase transaction 583,771 $17.13 $9,999,938.85 583,771.00
17 Apr 2023 Kim, Dennis D N/A Sell (option related) 112,219 $9.54 $1,070,535.59 20,000.00
13 Apr 2023 Kim, Dennis D N/A Sell (option related) 7,781 $8.98 $69,880.38 20,000.00
12 Sep 2023 AVORO CAPITAL ADVISORS LLC N/A Regular sell transaction (market) 1,800 $1.00 $1,799.40 300.00
13 Sep 2023 AVORO CAPITAL ADVISORS LLC N/A Regular sell transaction (market) 1,200 $1.07 $1,287.69 250.00

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Director deal information provided by Factset.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.